• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Recognizing Symptoms During Head and Neck Cancer Awareness Month

by MM360 Staff | Apr 18, 2025 | Uncategorized

Source: CureToday articles Dr. Zafar Sayed discuss the importance of recognizing Head and Neck Cancer Awareness Month and highlights early symptoms of the disease to be aware of. Read More

AI Tool May Better Predict Transplant Risk in Myelofibrosis

by MM360 Staff | Apr 18, 2025 | Uncategorized

Source: CureToday articles An AI model may help identify patients with myelofibrosis at high risk of early death after transplant, according to an expert. Read More

Daffodils and Determination from a Patient with Chronic Lymphocytic Leukemia

by MM360 Staff | Apr 18, 2025 | Uncategorized

Source: CureToday articles Each spring, I find strength and hope in the daffodils I grow, helping me face chronic lymphocytic leukemia with renewed determination. Read More

First Patient Dosed in a Phase 1/2 Trial for Small Cell Lung Cancer

by MM360 Staff | Apr 18, 2025 | Uncategorized

Source: CureToday articles The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus immune checkpoint inhibitors. Read More

First Patient with Colon Cancer Dosed in a Phase 2 Study of TCMCB07

by MM360 Staff | Apr 18, 2025 | Uncategorized

Source: CureToday articles The first patient has received TCMCB07 in a phase 2 trial to prevent weight loss in patients with metastatic colorectal cancer undergoing chemotherapy. Read More

Radiation Delay in NSCLC May Aid Outcomes, But Raises Toxicity Risks

by MM360 Staff | Apr 18, 2025 | Uncategorized

Source: CureToday articles Deferring upfront CNS-directed radiation in EGFR-variant and ALK-positive NSCLC may improve outcomes but raises treatment-related toxicity risks. Read More
« Older Entries
Next Entries »

Recent Content

  • (no title)
  • New center promotes advocacy for gynecological cancer patients
  • FDA clears Thermo Fisher EXTENT system for myeloma diagnosis
  • Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma
  • TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial
  • (no title)
  • (no title)
  • New ‘powerful’ lab test will help researchers explore blood cancer
  • Assessing the correlation between patient and family reported outcome measures and multiple myeloma clinical parameters
  • Defining the proteome of bone marrow plasma in multiple myeloma and monoclonal gammopathy of undetermined significance
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT